This study aimed to achieve a formulation for an additive to produce oxo-biodegradable films that accelerates oxidative degradation of the films after preservation of properties over a span of desired service life. Thermal oxidation behavior of high-density polyethylene (HDPE) films (approximately 250 lm thick) containing various weight ratios of a commercially used phenolic antioxidant (Irganox 1010) to ferric stearate as pro-oxidant has been studied in both melt and solid states. Thermooxidative stability in melt state was studied using differential scanning calorimetry. The rate of thermal oxidation in solid state was investigated via oven aging experiments at 90°C followed by measuring changes in tensile properties, gel content, carbonyl index and density. Comparing thermo-oxidative stability of the HDPE samples containing a combination of Irganox 1010 and ferric stearate with the samples containing Irganox 1010 alone confirmed that ferric stearate reduces the stabilization efficiency of the phenolic antioxidant in the polymer either in melt or in solid state. It was also shown that the efficiency of the phenolic antioxidant in thermo-oxidative stabilization of the polymer in both melt and solid states could be changed by altering weight ratio of Irganox 1010/ferric stearate. On the basis of the obtained results, it was concluded that weight ratio of 0.1/0.1 wt% of the antioxidant to the prooxidant is suitable for attaining desired stability during melt processing as well as retaining properties during a reasonable service life when is used as a film and a favorable rate of thermal oxidation after the service life.
Clonal hematopoiesis (CH) increases risk for the development of hematological malignancy and cardiovascular disease. IL1β is elevated in patients with CH and its inhibition mitigates cardiovascular risk in murine models with Tet2 loss-of-function. How IL1β alters population dynamics of hematopoietic cells upon Tet2 deletion (Tet2-KO) is not well understood. We demonstrated IL1β expands Tet2-KO neutrophils, monocytes/macrophages, and long-term hematopoietic stem cells with reduced lymphopoiesis. IL1β promoted myeloid bias over other lineages of Tet2-KO HSPCs coinciding with failure to demethylate lineage associated enhancer and transcription factor binding sites. IL1β enhanced the self-renewal ability of Tet2-KO HSPCs by upregulating genes associated with self-renewal potential and by resisting demethylation of binding sites of transcription factors promoting terminal differentiation. IL1β-mediated premalignant phenotype is reversed by IL1β antagonist anakinra or deletion of the Il1 receptor, in vivo. Our results demonstrated that targeting IL-1 signaling could be an efficient early intervention strategy in preleukemic disorders.
Background: Inflammation plays a crucial role in normal and malignant hematopoiesis. Patients with acute myeloid leukemia (AML) exhibit aberrant interleukin-1β (IL-1β) signaling which results in AML progression. Previously, we have shown that IL-1β promotes the expansion of leukemic progenitors while suppresses the growth of healthy cells. To understand this paradoxical effect, we applied transcriptome analysis of IL-1β-stimulated AML versus healthy progenitors and revealed differentially expressed genes involved in inflammation, cell cycle, and chromosome organization. We identified that ASF1B (anti-silencing function1B) is one of the highly expressed genes between AML and healthy progenitors upon IL-1β stimulation. ASF1B is a histone chaperone and delivers H3-H4 histone dimers onto DNA during replication and DNA damage response. ASF1B is overexpressed in various solid tumors and associated with poor prognosis. However, the functional roles of ASF1B in hematopoiesis and inflammation-driven leukemia have not been established. Methods and Results: We observed higher ASF1B expression in AML progenitors from various AML genetic subtypes (e.g. FLT3-ITD, NPM1, and MLL-ENL) compared to healthy cells at baseline levels and upon IL-1β stimulation. ASF1B upregulation is abolished upon treatment with a p38MAPK inhibitor, suggesting that ASF1B is downstream of IL-1β/p38 signaling. To determine whether ASF1B mediates IL-1β-driven leukemic growth, we overexpressed ASF1B with MLL-ENL oncogene in a murine bone marrow transplantation model. We found that IL-1β treatment accelerated AML progression compared to the vehicle-treated group (median survival = 64 vs. 85 days, P<0.05), and this effect was phenocopied by overexpression of ASF1B (median survival = 62 vs. 85 days, P<0.05). Conversely, both heterozygous and complete ASF1B deletion in the MLL-ENL AML model delayed the leukemia progression compared to wildtype mice (median survival = 67 and 68 days vs. 62 days, P<0.01). Additionally, ASF1B deletion attenuated IL-1β-mediated AML progression compared to wildtype controls (median survival = 63 vs. 47 days, P<0.01). Bone marrow and spleen cells harvested from the moribund mice exhibited myeloid phenotypes, indicating that observed survival differences are due to the impact of ASF1B deficiency on leukemic cell growth. Interestingly, immunophenotyping of Asf1b-deficient mice using flow cytometry suggested that ASF1B is dispensable for normal hematopoiesis. Conclusion: We demonstrate that the ASF1B pathway is activated in response to microenvironmental cues such as IL-1β in primary AML cells. In vivo evidence using murine AML and genetic models suggests that ASF1B contributes to IL-1β-driven AML progression. Therefore, we provide rationales for using ASF1B as a surrogate marker for AML progression and a safer therapeutic target to inhibit inflammation-driven growth in various AML genetic subtypes. Citation Format: Hsin-Yun Lin, Mona Mohammadhosseini, Marina Villamor, John McClatchy, Sophia Jeng, Andrew Adey, Shannon McWeeney, Travis Stracker, Anupriya Agarwal. Disruption of a histone chaperone pathway delays inflammation-driven AML progression [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 531.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.